Newly diagnosed with DVT and a pulmonary embolism, columnist Michelle Harlan finds herself in an unfamiliar relationship with ...
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live ...
Novo Nordisk (NYSE:NVO) is advancing etavopivat through late stage clinical trials as a potential therapy for thalassemia. The treatment is under ongoing regulatory review, focused on both beta and ...
All five patients in the trial received CS-101, a treatment developed by Chinese researchers, and achieved fast hematopoietic reconstruction. This process allows the body to restart its blood-making ...
I am deeply humbled by the decades of support from people around the world. It is an honor to share this painful yet ...
With 2,000–2,500 severe thalassemia cases diagnosed each year in Vietnam, expanded access to stem cell transplantation is ...
The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy ...
With a market cap of $112.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on ...
Researchers to examine the long-term effects of sickle cell disease, beta thalassemia, and acute leukaemias by linking health records across England: United Kingdom Friday, April ...
NANNING -- In a milestone for genetic medicine, researchers in China have reported the world's first clinical success using a ...
Early clinical results have shown that a single stem cell treatment has enabled patients with an inherited blood disorder, ...
Zacks Investment Research on MSN
AGIO rises on mitapivat progress toward accelerated approval in SCD
Shares of Agios Pharmaceuticals AGIO rallied 14% on Tuesday after the company announced its intention to seek accelerated approval for its lead drug, mitapivat, for the treatment of sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results